Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response

被引：3
作者：
Babushok, Daria V. [1 ,2 ]
Nelson, Ernest J. [3 ]
Morrissette, Jennifer J. D. [3 ]
Joshi, Shivam [4 ]
Palmer, Matthew B. [3 ]
Frank, Dale [3 ]
Cambor, Carolyn L. [3 ]
Hexner, Elizabeth O. [1 ]
机构：
[1] Hosp Univ Penn, Dept Med, Div Hematol Oncol, PCAM 12 South,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Hematol, Dept Pediat, Comprehens Bone Marrow Failure Ctr, Philadelphia, PA 19104 USA
[3] Hosp Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA
[4] Hosp Univ Penn, Dept Med, Div Nephrol, Philadelphia, PA 19104 USA
来源：
LEUKEMIA & LYMPHOMA | 2019年 / 60卷 / 03期
关键词：
THERAPY;
D O I：
10.1080/10428194.2018.1509319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：852 / 855
页数：4
相关论文
共 14 条
[1]  
AKIKUSA B, 1987, ARCH PATHOL LAB MED, V111, P525
[2]   Amyloidosis complicating idiopathic myelofibrosis [J].
Chan, KW ;
Ho, CP .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (06)
[3]   Secondary amyloidosis in the course of idiopathic myelofibrosis [J].
Ferhanoglu, B ;
Erzin, Y ;
Baslar, Z ;
Tuzuner, HAN .
LEUKEMIA RESEARCH, 1997, 21 (09) :897-898
[4]   JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis [J].
Harrison, Claire ;
Kiladjian, Jean-Jacques ;
Al-Ali, Haifa Kathrin ;
Gisslinger, Heinz ;
Waltzman, Roger ;
Stalbovskaya, Viktoriya ;
McQuitty, Mari ;
Hunter, Deborah S. ;
Levy, Richard ;
Knoops, Laurent ;
Cervantes, Francisco ;
Vannucchi, Alessandro M. ;
Barbui, Tiziano ;
Barosi, Giovanni .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09) :787-798
[5]   Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis [J].
Kremyanskaya, Marina ;
Mascarenhas, John ;
Rampal, Raajit ;
Hoffman, Ronald .
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (01) :144-146
[6]   Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis [J].
Kvasnicka, Hans Michael ;
Thiele, Juergen ;
Bueso-Ramos, Carlos E. ;
Sun, William ;
Cortes, Jorge ;
Kantarjian, Hagop M. ;
Verstovsek, Srdan .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[7]  
Kwon Youngmee, 2004, Ann Diagn Pathol, V8, P227, DOI 10.1053/j.anndiagpath.2004.04.006
[8]  
Leblebisatan Goksel, 2010, Hematol Oncol Stem Cell Ther, V3, P206
[9]   Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era? [J].
Lestang, Elsa ;
Peterlin, Pierre ;
Le Bris, Yannick ;
Dubruille, Viviane ;
Delaunay, Jacques ;
Godon, Catherine ;
Theisen, Olivier ;
Blin, Nicolas ;
Mahe, Beatrice ;
Gastinne, Thomas ;
Garnier, Alice ;
Touzeau, Cyrille ;
Voldoire, Maud ;
Bene, Marie C. ;
Le Gouill, Steven ;
Milpied, Noel ;
Mohty, Mohamad ;
Moreau, Philippe ;
Guillaume, Thierry ;
Chevallier, Patrice .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (01) :60-69
[10]   Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative disorders [J].
Remstein, ED ;
Kurtin, PJ ;
Nascimento, AG .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2000, 24 (01) :51-55
12